Eberlein, C. A., Stetson, D., Markovets, A. A., Al-Kadhimi, K. J., Lai, Z., Fisher, P. R., . . . Cross, D. A. E. (2015). Acquired resistance to mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res.
Citação norma ChicagoEberlein, Catherine A., et al. "Acquired Resistance to Mutant-selective EGFR Inhibitor AZD9291 Is Associated With Increased Dependence On RAS Signaling in Preclinical Models." Cancer Res 2015.
Citação norma MLAEberlein, Catherine A., et al. "Acquired Resistance to Mutant-selective EGFR Inhibitor AZD9291 Is Associated With Increased Dependence On RAS Signaling in Preclinical Models." Cancer Res 2015.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.